Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 risankizumab study in moderate to severe hidradenitis suppurativa
2019-000122-21Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of risankizumab in hidradenitis suppurativa (HS) (3 arms), sponsored by AbbVie Inc. Started Jul 2019; status: terminated.
02
Drugs
risankizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2019-000122-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000122-21.